Ability of the VITEK 2 advanced expert system to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa

被引:55
作者
Sanders, CC
Peyret, M
Moland, ES
Shubert, C
Thomson, KS
Boeufgras, JM
Sanders, WE
机构
[1] Creighton Univ, Ctr Res Anti Infect & Biotechnol, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA
[2] BioMerieux Inc, Hazelwood, MO 63042 USA
[3] BioMerieux, LaBalme Les Grottes, France
关键词
D O I
10.1128/JCM.38.2.570-574.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Advanced Expert System (AES) was used in conjunction with the VITEK 2 automated antimicrobial susceptibility test system to ascertain the p-lactam phenotypes of 196 isolates of the family Enterobacteriaeae and the species Pseudomonas aeruginosa. These isolates represented a panel of strains that had been collected from laboratories worldwide and whose beta-lactam phenotypes had been characterized by biochemical and molecular techniques. The antimicrobial susceptibility of each isolate tvas determined with the VITEK 2 instrument, and the results were analyzed with the AES to ascertain the beta-lactam phenotype. The results were then compared to the beta-lactam resistance mechanism determined by biochemical and molecular techniques. Overall, the AES was able to ascertain a beta-lactam phenotype for 183 of the 196 (93.4%) isolates tested. For 111 of these 183 (60.7%) isolates, the correct beta-lactam phenotype was identified definitively in a single choice by the AES, while for an additional 46 isolates (25.1%), the AES identified the correct beta-lactam phenotype provisionally within two or more choices. For the remaining 26 isolates (14.2%), the beta-lactam phenotype identified by the AES was incorrect. However, for a number of these isolates, the error nas due to remediable problems. These results suggest that the AES is capable of accurate identification of the beta-lactam phenotypes of gram-negative isolates and that certain modifications can improve its performance even further.
引用
收藏
页码:570 / 574
页数:5
相关论文
共 17 条
[1]   A NEW PLASMIDIC CEFOTAXIMASE IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].
BAUERNFEIND, A ;
GRIMM, H ;
SCHWEIGHART, S .
INFECTION, 1990, 18 (05) :294-298
[2]   DEVELOPMENT OF TEST PANEL OF BETA-LACTAMASES EXPRESSED IN A COMMON ESCHERICHIA-COLI HOST BACKGROUND FOR EVALUATION OF NEW BETA-LACTAM ANTIBIOTICS [J].
BRADFORD, PA ;
SANDERS, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :308-313
[3]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[4]  
Courvalin P., 1992, ASM NEWS, V58, P368, DOI DOI 10.1111/J.1469-0691.1996.TB00872.X
[5]   BETA-LACTAMASES IN LABORATORY AND CLINICAL RESISTANCE [J].
LIVERMORE, DM .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :557-&
[6]   USE OF ANALYTICAL ISOELECTRIC FOCUSING FOR DETECTION AND IDENTIFICATION OF BETA-LACTAMASES [J].
MATTHEW, M ;
HARRIS, AM ;
MARSHALL, MJ ;
ROSS, GW .
JOURNAL OF GENERAL MICROBIOLOGY, 1975, 88 (MAY) :169-178
[8]   Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of β-lactamase production among Escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? [J].
Moland, ES ;
Sanders, CC ;
Thomson, KS .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (09) :2575-2579
[9]  
*NAT COMM CLIN LAB, 1997, M7A4
[10]  
OCALLAGHAN CH, 1969, EFFECTS BETA LACTAMA, P57